January 2, 2018 / 1:16 PM / 19 days ago

BRIEF-Selecta Biosciences Announces FDA Acceptance Of Investigational New Drug Application For Lmb-100 And Svp-Rapamycin Combination Therapy

Jan 2 (Reuters) - Selecta Biosciences Inc:

* SELECTA BIOSCIENCES ANNOUNCES FDA ACCEPTANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR LMB-100 AND SVP-RAPAMYCIN COMBINATION THERAPY

* SELECTA BIOSCIENCES INC - ENROLLMENT OF UP TO 18 PATIENTS IS EXPECTED TO BEGIN AT NCI DURING Q1 OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below